Sinco Pharmaceuticals Holdings Balance Sheet Health
Financial Health criteria checks 5/6
Sinco Pharmaceuticals Holdings has a total shareholder equity of CN¥644.7M and total debt of CN¥327.3M, which brings its debt-to-equity ratio to 50.8%. Its total assets and total liabilities are CN¥1.8B and CN¥1.2B respectively. Sinco Pharmaceuticals Holdings's EBIT is CN¥131.5M making its interest coverage ratio 158.6. It has cash and short-term investments of CN¥282.0M.
Key information
50.8%
Debt to equity ratio
CN¥327.33m
Debt
| Interest coverage ratio | 158.6x |
| Cash | CN¥282.01m |
| Equity | CN¥644.70m |
| Total liabilities | CN¥1.17b |
| Total assets | CN¥1.82b |
Recent financial health updates
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
Nov 07
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
May 30Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet
Oct 26Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt
May 24Recent updates
Lacklustre Performance Is Driving Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 26% Price Drop
Nov 20What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You
Oct 04Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Aug 16Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings
Apr 02Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks
Mar 08Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
Nov 07A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Jun 26Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
May 30Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet
Oct 26Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today
Feb 04I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease
Oct 25Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings
Jun 10Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt
May 24Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock
Apr 20We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings
Feb 16How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 11
Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?
Dec 07Financial Position Analysis
Short Term Liabilities: 6833's short term assets (CN¥1.3B) exceed its short term liabilities (CN¥1.1B).
Long Term Liabilities: 6833's short term assets (CN¥1.3B) exceed its long term liabilities (CN¥29.9M).
Debt to Equity History and Analysis
Debt Level: 6833's net debt to equity ratio (7%) is considered satisfactory.
Reducing Debt: 6833's debt to equity ratio has reduced from 369.6% to 50.8% over the past 5 years.
Debt Coverage: 6833's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 6833's interest payments on its debt are well covered by EBIT (158.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 11:44 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sinco Pharmaceuticals Holdings Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Milo Liu | China Merchants Securities (HK) Co., Ltd |